The Efficacy of 12 Weeks of Sofosbuvir, Daclatasvir, and Ribavirin in Treating Hepatitis C Patients with Cirrhosis, Genotypes 1 and 3
| Author | Shahin Merat | en |
| Author | Amir Houshang Sharifi | en |
| Author | Arghavan Haj-Sheykholeslami | en |
| Author | Hossein Poustchi | en |
| Author | Babak Fattahi | en |
| Author | Alireza Nateghi-Baygi | en |
| Author | Seyed Moayed Alavian | en |
| Author | Reza Malekzadeh | en |
| Orcid | Reza Malekzadeh [0000-0003-1043-3814] | en |
| Issued Date | 2017-01-01 | en |
| Abstract | Background: The combination of sofosbuvir and daclatasvir can be used to treat all genotypes of hepatitis C. Current guidelines for treating hepatitis C cirrhosis do not clarify weather 12 weeks or 24 weeks of treatment is appropriate. Objectives: In the present study, we aimed at evaluating the efficacy of sofosbuvir, daclatasvir, and ribavirin given for 12 weeks in treating cirrhotic patients with hepatitis C genotypes 1 and 3 infections. Methods: One hundred patients with hepatitis C and cirrhosis infected with Genotypes 1 and 3 were included in the present study. They were treated with 1 tablet of a combination pill of 400 mg sofosbuvir and 60 mg daclatasvir daily and weight-based ribavirin for 12 weeks. Response to treatment was assessed 12 weeks after the end of the treatment with a sensitive assay (SVR12). This study was registered with ClinicalTrials.gov, ID: NCT02596880. Results: One patient developed increased creatinine level following severe diarrhea and gastroenteritis and was excluded, 1 patient died due to unrelated reasons and 4 others were lost to follow-up. Among the 94 patients who finished the study, 92 achieved SVR12 (98%, per-protocol, 92% intention-to-treat). None of the patients reported any side effects. Of the 100 original patients, 56 were Genotype 1 and 44 were Genotype 3. One of the two patients not achieving SVR12 was Genotype 1, and the other two were Genotype 3. Conclusions: The fixed-dose combination drug of sofosbuvir and daclatasvir given together with weight-base ribavirin for 12 weeks is extremely effective and safe in treating HCV patients with Genotypes 1 and 3 and cirrhosis. | en |
| DOI | https://doi.org/10.5812/hepatmon.44564 | en |
| Keyword | Hepatitis C | en |
| Keyword | Sofosbuvir | en |
| Keyword | Daclatasvir | en |
| Keyword | Sovodak | en |
| Publisher | Brieflands | en |
| Title | The Efficacy of 12 Weeks of Sofosbuvir, Daclatasvir, and Ribavirin in Treating Hepatitis C Patients with Cirrhosis, Genotypes 1 and 3 | en |
| Type | Research Article | en |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- 15699-pdf.pdf
- Size:
- 90.25 KB
- Format:
- Adobe Portable Document Format
- Description:
- Article/s PDF